Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting.

Liver international : official journal of the International Association for the Study of the Liver - 1 Jul 2015

Höner Zu Siederdissen Christoph, Maasoumy Benjamin, Deterding Katja, Port Kerstin, Sollik Lisa, Mix Carola, Kirschner Janina, Cornberg Janet, Manns Michael P, Wedemeyer Heiner, Cornberg Markus

Abstract excerpt

BACKGROUND & AIMS: Several real world data demonstrated that eligibility for and tolerability of triple therapy against hepatitis C virus (HCV) infection with a first-wave protease inhibitor is limited. With the approval of sofosbuvir (SOF) effective treatment with and without pegylated interferon (PEG-IFN) has become available for most genotypes. However, no data are available regarding the added benefit of an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hospitalization

Share to Interferon-alpha

Share to Patient Selection

Share to Polyethylene Glycols

Share to Ribavirin

Share to Sofosbuvir

Source

Identifiers

PMID: 25556625
DOI: 10.1111/liv.12774

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting.PMID 25556625Read ↗

Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program.Semantic proximity Read ↗

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era.Semantic proximity Read ↗

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.Semantic proximity Read ↗

Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.Semantic proximity Read ↗

Sofosbuvir for previously untreated chronic hepatitis C infection.Semantic proximity Read ↗

Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.Semantic proximity Read ↗

Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.Semantic proximity Read ↗

Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients.Semantic proximity Read ↗

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.Semantic proximity Read ↗

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.Semantic proximity Read ↗

Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection.Semantic proximity Read ↗

Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.